

Andrew Coats

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3722556/publications.pdf>

Version: 2024-02-01

428
papers

70,928
citations

2423

97
h-index

631

257
g-index

447
all docs

447
docs citations

447
times ranked

41529
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
3	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
4	Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine, 2001, 344, 1651-1658.	13.9	2,909
5	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
6	Ethical authorship and publishing. International Journal of Cardiology, 2009, 131, 149-150.	0.8	2,087
7	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal, 2005, 26, 215-225.	1.0	1,392
8	Wasting as independent risk factor for mortality in chronic heart failure. Lancet, The, 1997, 349, 1050-1053.	6.3	1,209
9	Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure. Circulation, 2002, 106, 2194-2199.	1.6	1,132
10	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
11	Ethics in the authorship and publishing of scientific articles. International Journal of Cardiology, 2010, 144, 1-2.	0.8	812
12	Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, The, 1999, 353, 1838-1842.	6.3	788
13	Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet, The, 1997, 350, 1349-1353.	6.3	775
14	Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure. Circulation, 2000, 102, 3060-3067.	1.6	723
15	Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia. Circulation, 1997, 96, 526-534.	1.6	671
16	Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet, The, 2003, 361, 1077-1083.	6.3	648
17	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
18	Reduction in Sample Size for Studies of Remodeling in Heart Failure by the Use of Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance, 2000, 2, 271-278.	1.6	583

#	ARTICLE	IF	CITATIONS
19	Uric Acid and Survival in Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1991-1997.	1.6	532
20	Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure. <i>Circulation</i> , 2002, 105, 2619-2624.	1.6	518
21	Global burden of heart failure: a comprehensive and updated review of epidemiology. <i>Cardiovascular Research</i> , 2023, 118, 3272-3287.	1.8	517
22	Clinical Correlates and Prognostic Significance of the Ventilatory Response to Exercise in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 1585-1590.	1.2	505
23	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	2.9	490
24	The endotoxin-lipoprotein hypothesis. <i>Lancet</i> , The, 2000, 356, 930-933.	6.3	482
25	Insulin Resistance in Chronic Heart Failure: Relation to Severity and Etiology of Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 30, 527-532.	1.2	475
26	Survival of patients with a new diagnosis of heart failure: a population based study. <i>British Heart Journal</i> , 2000, 83, 505-510.	2.2	474
27	Exercise limitation in chronic heart failure: Central role of the periphery. <i>Journal of the American College of Cardiology</i> , 1996, 28, 1092-1102.	1.2	464
28	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019, 21, 715-731.	2.9	446
29	Contribution of Muscle Afferents to the Hemodynamic, Autonomic, and Ventilatory Responses to Exercise in Patients With Chronic Heart Failure. <i>Circulation</i> , 1996, 93, 940-952.	1.6	445
30	Depressed Heart Rate Variability as an Independent Predictor of Death in Chronic Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 1997, 79, 1645-1650.	0.7	436
31	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018, 39, 26-35.	1.0	426
32	Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2150-2158.	1.2	405
33	Neurohormonal Activation and the Chronic Heart Failure Syndrome in Adults With Congenital Heart Disease. <i>Circulation</i> , 2002, 106, 92-99.	1.6	369
34	Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. <i>BMJ: British Medical Journal</i> , 2000, 320, 1128-1134.	2.4	366
35	Intraventricular conduction delay: a prognostic marker in chronic heart failure. <i>International Journal of Cardiology</i> , 1999, 70, 171-178.	0.8	365
36	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the ESC-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. <i>European Journal of Heart Failure</i> , 2020,	2.9	364

#	ARTICLE	IF	CITATIONS
37	The relationship between cholesterol and survival in patients with chronic heart failure. Journal of the American College of Cardiology, 2003, 42, 1933-1940.	1.2	361
38	Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. American Journal of Cardiology, 1997, 79, 1426-1430.	0.7	358
39	Skeletal Muscle Function and Its Relation to Exercise Tolerance in Chronic Heart Failure. Journal of the American College of Cardiology, 1997, 30, 1758-1764.	1.2	352
40	Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Preserved Exercise Tolerance. Circulation, 2001, 103, 967-972.	1.6	348
41	Cardiac Cachexia. Chest, 1999, 115, 836-847.	0.4	346
42	Physical training improves skeletal muscle metabolism in patients with chronic heart failure. Journal of the American College of Cardiology, 1993, 21, 1101-1106.	1.2	338
43	How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. International Journal of Cardiology, 2002, 86, 123-130.	0.8	335
44	Short report: An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices. Journal of Hypertension, 1993, 11, 677-679.	0.3	325
45	Exercise-based rehabilitation for heart failure. The Cochrane Library, 2014, , CD003331.	1.5	320
46	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	1.0	304
47	Statement on authorship and publishing ethics in the international journal of cardiology. International Journal of Cardiology, 2011, 153, 239-240.	0.8	300
48	Prognostic Impact of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure. Circulation, 2004, 110, 1780-1786.	1.6	282
49	Body mass and survival in patients with chronic heart failure without cachexia: The importance of obesity. Journal of Cardiac Failure, 2003, 9, 29-35.	0.7	281
50	Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) Trial support the use of bosentan in heart failure? Journal of Cardiology, 2002, 85, 195-197.	0.8	277
51	Peripheral Chemoreceptor Hypersensitivity. Circulation, 2001, 104, 544-549.	1.6	264
52	Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2003, 289, 712.	3.8	261
53	Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. European Journal of Heart Failure, 2010, 12, 706-715.	2.9	261
54	Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. Journal of the American College of Cardiology, 1996, 27, 650-657.	1.2	260

#	ARTICLE	IF	CITATIONS
55	Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1019-1026.	1.2	249
56	Exercise-based cardiac rehabilitation for adults with heart failure. <i>The Cochrane Library</i> , 2019, 2019, CD003331.	1.5	247
57	Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fasligand system in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 39, 653-663.	1.2	228
58	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	2.9	224
59	Augmented Peripheral Chemosensitivity as a Potential Input to Baroreflex Impairment and Autonomic Imbalance in Chronic Heart Failure. <i>Circulation</i> , 1997, 96, 2586-2594.	1.6	221
60	Muscle Ergoreceptor Overactivity Reflects Deterioration in Clinical Status and Cardiorespiratory Reflex Control in Chronic Heart Failure. <i>Circulation</i> , 2001, 104, 2324-2330.	1.6	208
61	Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 753-762.	1.2	203
62	Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. <i>Journal of the American College of Cardiology</i> , 2001, 38, 443-452.	1.2	200
63	Oscillatory Breathing Patterns During Wakefulness in Patients With Chronic Heart Failure. <i>Circulation</i> , 1999, 100, 2418-2424.	1.6	196
64	Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. <i>European Heart Journal</i> , 2006, 27, 684-690.	1.0	185
65	Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. <i>Journal of the American College of Cardiology</i> , 1998, 32, 393-397.	1.2	183
66	Tumor Necrosis Factor and Steroid Metabolism in Chronic Heart Failure: Possible Relation to Muscle Wasting. <i>Journal of the American College of Cardiology</i> , 1997, 30, 997-1001.	1.2	181
67	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 157-174.	2.9	181
68	Quantitative General Theory for Periodic Breathing in Chronic Heart Failure and its Clinical Implications. <i>Circulation</i> , 2000, 102, 2214-2221.	1.6	174
69	Estrogen acutely increases peripheral blood flow in postmenopausal women. <i>American Journal of Medicine</i> , 1995, 99, 119-122.	0.6	173
70	Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. <i>European Heart Journal</i> , 2004, 25, 1021-1028.	1.0	170
71	Acute heart failure congestion and perfusion status—Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170
72	Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2002, 4, 541-551.	2.9	167

#	ARTICLE	IF	CITATIONS
73	Oscillatory Ventilation During Exercise in Patients With Chronic Heart Failure. <i>Chest</i> , 2002, 121, 1572-1580.	0.4	164
74	Albumin levels predict survival in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2012, 14, 39-44.	2.9	161
75	The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. <i>International Journal of Cardiology</i> , 2000, 72, 175-186.	0.8	160
76	Exercise based rehabilitation for heart failure. , 2004, , CD003331.		150
77	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 54-65.	2.9	150
78	Task Force V: White-coat hypertension. <i>Blood Pressure Monitoring</i> , 1999, 4, 333-341.	0.4	146
79	Effects of Dihydrocodeine on Chemosensitivity and Exercise Tolerance in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 147-152.	1.2	136
80	Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1423-1429.	1.2	132
81	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	2.9	131
82	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. <i>European Journal of Heart Failure</i> , 2021, 23, 906-914.	2.9	130
83	Autonomic Control of Skin Microvessels: Assessment by Power Spectrum of Photoplethysmographic Waves. <i>Clinical Science</i> , 1996, 90, 345-355.	1.8	126
84	A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure. <i>American Heart Journal</i> , 1999, 137, 1050-1056.	1.2	126
85	Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 355-365.	2.9	126
86	Cardiac effects of exercise rehabilitation in hemodialysis patients. <i>International Journal of Cardiology</i> , 1999, 70, 253-266.	0.8	125
87	Effect of anemia on exercise tolerance in chronic heart failure in men. <i>American Journal of Cardiology</i> , 2003, 91, 888-891.	0.7	125
88	Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2001, 87, 737-742.	0.7	123
89	Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. <i>American Journal of Cardiology</i> , 2003, 92, 188-193.	0.7	123
90	Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. <i>International Journal of Cardiology</i> , 2000, 76, 125-133.	0.8	122

#	ARTICLE	IF	CITATIONS
91	Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. Journal of the American College of Cardiology, 2001, 37, 1808-1812.	1.2	122
92	Loss of bone mineral in patients with cachexia due to chronic heart failure. American Journal of Cardiology, 1999, 83, 612-615.	0.7	115
93	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	2.9	115
94	Predictors of clinical outcomes in elderly patients with heart failure. European Journal of Heart Failure, 2011, 13, 528-536.	2.9	109
95	Muscle Metaboreflex-Induced Increases in Stroke Volume. Medicine and Science in Sports and Exercise, 2003, 35, 221-228.	0.2	108
96	Exercise based rehabilitation for heart failure. , 2010, , CD003331.		108
97	The regulation and measurement of plasma volume in heart failure. Journal of the American College of Cardiology, 2002, 39, 1901-1908.	1.2	107
98	EXPLAINING FATIGUE IN CONGESTIVE HEART FAILURE. Annual Review of Medicine, 1996, 47, 241-256.	5.0	104
99	Diuretics for heart failure. , 2012, , CD003838.		103
100	A qualitative study of chronic heart failure patientsâ€™ understanding of their symptoms and drug therapy. European Journal of Heart Failure, 2002, 4, 283-287.	2.9	98
101	Omapatrilat- the story of Overture and Octave. International Journal of Cardiology, 2002, 86, 1-4.	0.8	96
102	Abnormal autonomic control of the cardiovascular system in syndrome X. American Journal of Cardiology, 1994, 73, 1174-1179.	0.7	95
103	Congenital heart disease: the original heart failure syndrome. European Heart Journal, 2003, 24, 970-976.	1.0	95
104	Comparison of different methods for assessing sympathovagal balance in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology, 1992, 70, 1576-1582.	0.7	92
105	Incremental changes in QRS duration in serial ECGs over time identify high risk elderly patients with heart failure. British Heart Journal, 2002, 88, 47-51.	2.2	92
106	Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance. American Heart Journal, 2001, 141, 792-799.	1.2	90
107	Statin use and survival in patients with chronic heart failure â€“ results from two observational studies with 5200 patients. International Journal of Cardiology, 2006, 112, 234-242.	0.8	90
108	Ethical guidelines for authorship and publishing in the <i>Journal of Cachexia, Sarcopenia and Muscle</i>. Journal of Cachexia, Sarcopenia and Muscle, 2010, 1, 7-8.	2.9	88

#	ARTICLE	IF	CITATIONS
109	Reproducibility of methods for assessing baroreflex sensitivity in normal controls and in patients with chronic heart failure. <i>Clinical Science</i> , 1999, 97, 515-522.	1.8	86
110	Contribution of skeletal muscle "ergoreceptors"™ in the human leg to respiratory control in chronic heart failure. <i>Journal of Physiology</i> , 2000, 529, 863-870.	1.3	86
111	The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. <i>Journal of Hypertension</i> , 1992, 10, 385-391.	0.3	85
112	NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. <i>European Journal of Heart Failure</i> , 2004, 6, 343-350.	2.9	85
113	Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. <i>European Journal of Heart Failure</i> , 2009, 11, 872-880.	2.9	85
114	Establishment and Performance of a Magnetic Resonance Cardiac Function Clinic. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2000, 2, 15-22.	1.6	84
115	Unravelling the interplay between hyperkalaemia, renin"angiotensin"aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC"EHFA"EFORP Heart Failure Long"Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
116	Heart failure 99 " the Moxcon story. <i>International Journal of Cardiology</i> , 1999, 71, 109-111.	0.8	81
117	Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. <i>International Journal of Cardiology</i> , 2004, 96, 397-401.	0.8	81
118	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (<sc>US</sc>, <sc>UK</sc> and Sweden). <i>European Journal of Heart Failure</i> , 2021, 23, 1499-1511.	2.9	80
119	Physiological basis of fractal complexity properties of heart rate variability in man. <i>Journal of Physiology</i> , 2002, 542, 619-629.	1.3	78
120	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	1.0	78
121	HIGH TUMOUR NECROSIS FACTOR-Î± LEVELS ARE ASSOCIATED WITH EXERCISE INTOLERANCE AND NEUROHORMONAL ACTIVATION IN CHRONIC HEART FAILURE PATIENTS. <i>Cytokine</i> , 2001, 15, 80-86.	1.4	77
122	Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2002, 90, 384-389.	0.7	77
123	Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2002, 90, 1226-1230.	0.7	77
124	Haemoglobin concentration and prognosis in new cases of heart failure. <i>Lancet</i> , The, 2003, 362, 211-212.	6.3	76
125	A statement on ethical standards in publishing scientific articles in the International Journal of Cardiology family of journals. <i>International Journal of Cardiology</i> , 2014, 170, 253-254.	0.8	76
126	Insulin Resistance in Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, S9-S14.	0.8	76

#	ARTICLE	IF	CITATIONS
127	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 585-592.	1.2	74
128	Relation between ventilation and carbon dioxide production in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1992, 20, 1326-1332.	1.2	73
129	Right Ventricular Dysfunction in Adult Severe Cystic Fibrosis. <i>Chest</i> , 2000, 118, 1063-1068.	0.4	73
130	Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. <i>International Journal of Cardiology</i> , 2002, 83, 73-81.	0.8	72
131	Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 549-556.	2.9	71
132	Relationship between detrended fluctuation analysis and spectral analysis of heart-rate variability. <i>Physiological Measurement</i> , 2002, 23, 385-401.	1.2	69
133	Skeletal Muscle Reflex in Heart Failure Patients. <i>Circulation</i> , 2003, 107, 300-306.	1.6	69
134	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	0.7	68
135	Chemical Mediators of the Muscle Ergoreflex in Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 214-220.	1.6	67
136	Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. <i>American Heart Journal</i> , 2007, 154, 109-115.	1.2	67
137	Differential contribution of dead space ventilation and low arterial pCO ₂ to exercise hyperpnea in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 2004, 93, 318-323.	0.7	65
138	Chronic heart failure with preserved left ventricular ejection fraction: Diagnostic and prognostic value of left atrial size. <i>International Journal of Cardiology</i> , 2006, 110, 386-392.	0.8	65
139	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
140	Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. <i>International Journal of Cardiology</i> , 2002, 86, 225-231.	0.8	64
141	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1746-1754.	2.9	64
142	Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. <i>European Journal of Heart Failure</i> , 2011, 13, 656-663.	2.9	62
143	Detection and significance of a discrete very low frequency rhythm in RR interval variability in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1996, 77, 1320-1326.	0.7	61
144	Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1998, 82, 338-344.	0.7	60

#	ARTICLE	IF	CITATIONS
145	The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , 2000, 36, 523-528.	1.2	60
146	Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 179-186.	1.2	60
147	The anabolic catabolic transforming agent (ACTA) espidolol increases muscle mass and decreases fat mass in old rats. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 149-158.	2.9	58
148	Nonsurgical Reduction of the Interventricular Septum in Patients with Hypertrophic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2002, 347, 1326-1333.	13.9	57
149	Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. <i>International Journal of Cardiology</i> , 2012, 161, 156-159.	0.8	57
150	Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. <i>International Journal of Cardiology</i> , 1998, 66, 1-10.	0.8	54
151	The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS). <i>European Journal of Heart Failure</i> , 1999, 1, 191-196.	2.9	54
152	Consumer involvement in cardiovascular research: ways to combat bias and secrecy. <i>International Journal of Cardiology</i> , 2000, 75, 1-3.	0.8	54
153	Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS).. <i>International Journal of Cardiology</i> , 2002, 86, 77-85.	0.8	54
154	Exercise training in chronic heart failure: effects on pro-inflammatory markers. <i>European Journal of Heart Failure</i> , 2005, 7, 189-193.	2.9	54
155	The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer:. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 201-207.	2.9	53
156	Mechanical Support in Dilated Cardiomyopathy: Signs of Early Left Ventricular Recovery. <i>Annals of Thoracic Surgery</i> , 1997, 64, 1303-1308.	0.7	52
157	Echocardiography-derived variables predict outcome in patients with nonischemic dilated cardiomyopathy with or without a restrictive filling pattern. <i>American Heart Journal</i> , 2002, 144, 343-350.	1.2	52
158	Redefining β -blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. <i>Lancet</i> , The, 2021, 398, 1427-1435.	6.3	52
159	Global Impairment of Cardiac Autonomic Nervous Activity Late After Repair of Tetralogy of Fallot. <i>Circulation</i> , 2002, 106, .	1.6	51
160	Physical Training Enhances Sympathetic and Parasympathetic Control of Heart Rate and Peripheral Vessels in Chronic Heart Failure. <i>Clinical Science</i> , 1996, 91, 92-94.	0.0	50
161	Left ventricular remodelling: common process in patients with different primary myocardial disorders. <i>International Journal of Cardiology</i> , 1999, 68, 281-287.	0.8	50
162	Gender differences in the urinary excretion rates of cortisol and androgen metabolites. <i>Annals of Clinical Biochemistry</i> , 2000, 37, 770-774.	0.8	50

#	ARTICLE	IF	CITATIONS
163	Chronic heart failure in the very elderly: Clinical status, survival, and prognostic factors in 188 patients more than 70 years old. <i>American Heart Journal</i> , 2001, 142, 174-180.	1.2	50
164	Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: Negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. <i>Journal of Medical Virology</i> , 2004, 74, 147-155.	2.5	50
165	How high can a correlation coefficient be? Effects of limited reproducibility of common cardiological measures. <i>International Journal of Cardiology</i> , 1999, 69, 185-189.	0.8	49
166	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the ESC-HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	2.9	49
167	Effect of reduced muscle bulk on the ventilatory response to exercise in chronic congestive heart failure secondary to idiopathic dilated and ischemic cardiomyopathy. <i>American Journal of Cardiology</i> , 1997, 80, 90-93.	0.7	48
168	Global Impairment of Cardiac Autonomic Nervous Activity Late After the Fontan Operation. <i>Circulation</i> , 2003, 108, 180II-185.	1.6	48
169	Uric acid in chronic heart failure: A measure of the anaerobic threshold. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 1156-1159.	1.5	47
170	Mechanisms of exercise intolerance in congestive heart failure. <i>Current Opinion in Cardiology</i> , 1997, 12, 224-232.	0.8	46
171	Femoral haemostasis after transcatheter therapeutic intervention: a prospective randomised study of the angio-seal device vs. the femostop device. <i>International Journal of Cardiology</i> , 2000, 76, 235-240.	0.8	46
172	Origin of Oscillatory Kinetics of Respiratory Gas Exchange in Chronic Heart Failure. <i>Circulation</i> , 1999, 100, 1065-1070.	1.6	44
173	Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. <i>Journal of Cardiac Failure</i> , 2004, 10, 421-426.	0.7	44
174	Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. <i>International Journal of Cardiology</i> , 2010, 138, 19-24.	0.8	44
175	Ambulatory pressure monitoring in the assessment of antihypertensive therapy. <i>Cardiovascular Drugs and Therapy</i> , 1989, 3, 303-311.	1.3	43
176	Variability of Phase Shift Between Blood Pressure and Heart Rate Fluctuations. <i>Circulation</i> , 2003, 108, 292-297.	1.6	43
177	Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a β -blocker). <i>International Journal of Cardiology</i> , 2004, 93, 105-111.	0.8	43
178	Adherence to ethical standards in publishing scientific articles: A statement from the International Journal of Cardiology. <i>International Journal of Cardiology</i> , 2012, 161, 124-125.	0.8	43
179	Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. <i>International Journal of Cardiology</i> , 2016, 212, 1-10.	0.8	43
180	Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. <i>Journal of Hypertension</i> , 1994, 12, 1053-1060.	0.3	42

#	ARTICLE	IF	CITATIONS
181	A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. <i>European Journal of Heart Failure</i> , 2000, 2, 423-429.	2.9	42
182	Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins. <i>European Journal of Heart Failure</i> , 2005, 7, 479-484.	2.9	42
183	Angiotensin-converting enzyme (ACE) inhibitors revert abnormal right ventricular filling in patients with restrictive left ventricular disease. <i>Journal of the American College of Cardiology</i> , 1998, 32, 1187-1193.	1.2	41
184	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.	0.6	40
185	Reproducibility of methods for assessing baroreflex sensitivity in normal controls and in patients with chronic heart failure. <i>Clinical Science</i> , 1999, 97, 515.	1.8	39
186	Effect of altering conditions of the sequence method on baroreflex sensitivity. <i>Journal of Hypertension</i> , 2001, 19, 1279-1287.	0.3	39
187	The epidemiological enigma of heart failure with preserved systolic function. <i>European Journal of Heart Failure</i> , 2004, 6, 125-136.	2.9	38
188	Home-based exercise training modulates pro-oxidant substrates in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 183-188.	2.9	38
189	Peripheral chemoreflex in chronic heart failure: Friend and foe. <i>American Heart Journal</i> , 1996, 132, 900-904.	1.2	37
190	Metabolic, functional, and haemodynamic staging for CHF?. <i>Lancet</i> , The, 1996, 348, 1530-1531.	6.3	37
191	The cardiac component of cardiac cachexia. <i>American Heart Journal</i> , 2002, 144, 45-50.	1.2	37
192	Time is prognosis in heart failure: time to treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453.	1.4	37
193	The effect of salbutamol on skeletal muscle in chronic heart failure. <i>International Journal of Cardiology</i> , 2000, 73, 257-265.	0.8	36
194	Relationship of skeletal muscle metaboreceptors in the upper and lower limbs with the respiratory control in patients with heart failure. <i>Clinical Science</i> , 2002, 102, 23-30.	1.8	36
195	β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. <i>Heart</i> , 2011, 97, 209-214.	1.2	36
196	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-ORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
197	The role of exercise training in chronic heart failure. <i>Heart</i> , 1997, 78, 431-436.	1.2	35
198	True shape and area of proximal isovelocity surface area (PISA) when flow convergence is hemispherical in valvular regurgitation. <i>International Journal of Cardiology</i> , 2000, 73, 237-242.	0.8	35

#	ARTICLE	IF	CITATIONS
199	The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty. <i>International Journal of Cardiology</i> , 2002, 83, 249-257.	0.8	35
200	Physical function and exercise training in older patients with heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 550-559.	6.1	35
201	Do Optimal Prognostic Thresholds in Continuous Physiological Variables Really Exist? Analysis of Origin of Apparent Thresholds, with Systematic Review for Peak Oxygen Consumption, Ejection Fraction and BNP. <i>PLoS ONE</i> , 2014, 9, e81699.	1.1	35
202	Top of the charts: Download versus citations in the <i>International Journal of Cardiology</i> . <i>International Journal of Cardiology</i> , 2005, 105, 123-125.	0.8	34
203	Ageing, demographics, and heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, L4-L7.	0.0	34
204	Oxygenation in Patients With a Functionally Univentricular Circulation and Complete Mixing of Blood. <i>Circulation</i> , 1999, 100, 2198-2203.	1.6	33
205	Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. <i>International Journal of Cardiology</i> , 2002, 85, 133-139.	0.8	33
206	Beta-blocker therapy for dynamic left-ventricular outflow tract obstruction. <i>International Journal of Cardiology</i> , 2002, 86, 199-205.	0.8	33
207	Aerobic exercise physiology in a professional rugby union team. <i>International Journal of Cardiology</i> , 2003, 87, 173-177.	0.8	33
208	Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. <i>International Journal of Cardiology</i> , 2004, 97, 15-20.	0.8	33
209	COUNTERPOINT: INCREASED METABORECEPTOR STIMULATION EXPLAINS THE EXAGGERATED EXERCISE PRESSOR REFLEX SEEN IN HEART FAILURE. <i>Journal of Applied Physiology</i> , 2007, 102, 494-496.	1.2	32
210	Research on cachexia, sarcopenia and skeletal muscle in cardiology. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 219-223.	2.9	32
211	Mechanisms of exercise intolerance in cardiac failure. <i>Current Opinion in Cardiology</i> , 1994, 9, 305-314.	0.8	31
212	Reproducibility of Heart Rate Variability Measures in Patients with Chronic Heart Failure. <i>Clinical Science</i> , 1996, 91, 391-398.	1.8	31
213	Treating chronic heart failure: time to take stock. <i>Lancet, The</i> , 1997, 349, 966-967.	6.3	30
214	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. <i>Clinical Science</i> , 1999, 97, 503-513.	1.8	30
215	Patient descriptions of breathlessness in heart failure. <i>International Journal of Cardiology</i> , 2005, 98, 61-66.	0.8	30
216	Heart transplantation in heart failure: The prognostic importance of body mass index at time of surgery and subsequent weight changes. <i>European Journal of Heart Failure</i> , 2007, 9, 839-844.	2.9	30

#	ARTICLE	IF	CITATIONS
217	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 132-142.	2.9	30
218	Hemodynamic effects of captopril and isosorbide mononitrate started early in acute myocardial infarction: A randomized placebo-controlled study. <i>Journal of the American College of Cardiology</i> , 1993, 22, 73-79.	1.2	29
219	Central and peripheral components of chronic heart failure: determinants of exercise tolerance. <i>International Journal of Cardiology</i> , 1999, 70, 51-56.	0.8	29
220	Different response of patients with idiopathic and ischaemic dilated cardiomyopathy to exercise training. <i>International Journal of Cardiology</i> , 2000, 74, 215-224.	0.8	29
221	Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. <i>American Journal of Cardiology</i> , 1996, 77, 942-947.	0.7	28
222	Long-Term Cost-Effectiveness Analysis of Nebivolol Compared with Standard Care in Elderly Patients with Heart Failure. <i>Pharmacoeconomics</i> , 2008, 26, 879-889.	1.7	28
223	Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. <i>American Journal of Cardiology</i> , 1999, 83, 112-114.	0.7	27
224	A noninvasive measure of baroreflex sensitivity without blood pressure measurement. <i>American Heart Journal</i> , 2002, 143, 441-447.	1.2	27
225	Daytime ambulatory systolic blood pressure is more effective at predicting mortality than clinic blood pressure. <i>Blood Pressure Monitoring</i> , 2006, 11, 111-118.	0.4	27
226	Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. <i>Journal of Cardiac Failure</i> , 1996, 2, 177-183.	0.7	25
227	Putative contribution of prostaglandin and bradykinin to muscle reflex hyperactivity in patients on ACE-inhibitor therapy for chronic heart failure. <i>European Heart Journal</i> , 2004, 25, 1806-1813.	1.0	25
228	Contemporary (post-Wills) survey of the views of Australian medical researchers: importance of funding, infrastructure and motivators for a research career. <i>Medical Journal of Australia</i> , 2005, 183, 606-611.	0.8	25
229	Advances in the non-drug, non-surgical, non-device management of chronic heart failure. <i>International Journal of Cardiology</i> , 2005, 100, 1-4.	0.8	25
230	Cellular endotoxin desensitization in patients with severe chronic heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 865-868.	2.9	23
231	Measurement accuracy of cardiac output in humans: Indicator-dilution technique versus geometric analysis by ultrafast computed tomography. <i>Journal of the American College of Cardiology</i> , 1993, 21, 1482-1489.	1.2	22
232	Three year mortality in heart failure patients with very low left ventricular ejection fractions. <i>International Journal of Cardiology</i> , 1999, 70, 245-247.	0.8	22
233	Is central nervous system processing altered in patients with heart failure?. <i>European Heart Journal</i> , 2004, 25, 952-962.	1.0	22
234	The Management of Heart Failure with Preserved Ejection Fraction (HFpEF). <i>International Cardiovascular Forum Journal</i> , 2015, 1, 108.	1.1	22

#	ARTICLE	IF	CITATIONS
235	Common Co-Morbidities in Heart Failure – Diabetes, Functional Mitral Regurgitation and Sleep Apnoea. <i>International Journal of Heart Failure</i> , 2019, 1, 25.	0.9	22
236	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2022, 24, 406-420.	2.9	22
237	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125-132.	1.8	21
238	Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. <i>American Journal of Cardiology</i> , 2000, 86, 158-161.	0.7	21
239	??-Adrenoceptor Antagonists in Elderly Patients with Chronic Heart Failure. <i>Drugs and Aging</i> , 2006, 23, 93-99.	1.3	21
240	The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2006, 8, 366-372.	2.9	21
241	The epidemiology of heart failure in Australia. <i>International Journal of Cardiology</i> , 2007, 118, 370-374.	0.8	21
242	Comparing the Effects of White Coat Hypertension and Sustained Hypertension on Mortality in a UK Primary Care Setting. <i>Annals of Family Medicine</i> , 2008, 6, 390-396.	0.9	21
243	Exercise training in heart failure. , 2000, 1, 155.		20
244	Ventilatory capacity and exercise tolerance in patients with chronic stable heart failure. <i>European Journal of Heart Failure</i> , 2000, 2, 47-51.	2.9	20
245	Medical malpractice, murder and the academic community: trouble ahead. <i>International Journal of Cardiology</i> , 2001, 79, 1-4.	0.8	20
246	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
247	Ambulatory blood pressure monitoring and circadian variation of cardiovascular disease; clinical and research applications. <i>International Journal of Cardiology</i> , 1992, 36, 135-149.	0.8	19
248	The Time Course of Haemodynamic, Autonomic and Skeletal Muscle Metabolic Abnormalities Following First Extensive Myocardial Infarction in Man. <i>Journal of Molecular and Cellular Cardiology</i> , 1999, 31, 1913-1926.	0.9	19
249	Impact of periodic breathing on measurement of oxygen uptake and respiratory exchange ratio during cardiopulmonary exercise testing. <i>Clinical Science</i> , 2002, 103, 543-552.	1.8	19
250	Obesity Paradox as a Component of Reverse Epidemiology in Heart Failure. <i>Archives of Internal Medicine</i> , 2005, 165, 1797.	4.3	19
251	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. <i>Clinical Science</i> , 1999, 97, 503.	1.8	18
252	Relation of changes over time in ventricular size and function to those in exercise capacity in patients with chronic heart failure. <i>American Heart Journal</i> , 2000, 139, 913-917.	1.2	18

#	ARTICLE	IF	CITATIONS
253	Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications. <i>International Journal of Cardiology</i> , 2014, 174, 702-709.	0.8	18
254	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. <i>European Journal of Internal Medicine</i> , 2021, 89, 65-75.	1.0	18
255	Effects of mild physical activity, atenolol and the combination on ambulatory blood pressure in hypertensive subjects. <i>Journal of Hypertension</i> , 1992, 10, 1279-1282.	0.3	17
256	Is preventive medicine responsible for the increasing prevalence of heart failure?. <i>Lancet</i> , The, 1998, 352, S139-S141.	6.3	17
257	Bi-ventricular pacing in congestive cardiac failure. Current experience and future directions. <i>European Heart Journal</i> , 2000, 21, 884-889.	1.0	17
258	The relationship between age and production of tumour necrosis factor- α in healthy volunteers and patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2003, 90, 197-204.	0.8	17
259	Reproducibility of Heart Rate Variability Indices during Exercise Stress Testing and Inotrope Infusion in Chronic Heart Failure Patients. <i>Clinical Science</i> , 1996, 91, 87-88.	0.0	16
260	Neurobiology of exaggerated heart rate oscillations during two meditative techniques. <i>International Journal of Cardiology</i> , 2000, 73, 199.	0.8	16
261	Exercise hyperventilation in chronic heart failure is not caused by systemic lactic acidosis. <i>European Journal of Heart Failure</i> , 2005, 7, 1105-1111.	2.9	16
262	The incidence of cancer deaths among hypertensive patients in a large Chinese population: A cohort study. <i>International Journal of Cardiology</i> , 2015, 179, 178-185.	0.8	16
263	Ventilation-perfusion matching in chronic heart failure. <i>International Journal of Cardiology</i> , 1995, 48, 259-270.	0.8	15
264	Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 685-692.	1.3	14
265	Beta-blockers "again, a lesson to us all, especially the research funding community. <i>International Journal of Cardiology</i> , 2000, 73, 103-104.	0.8	14
266	Echocardiographic features and brain natriuretic peptides in patients presenting with heart failure and preserved systolic function. <i>Heart</i> , 2006, 92, 603-608.	1.2	14
267	Clinical utility of exercise training in chronic systolic heart failure. <i>Nature Reviews Cardiology</i> , 2011, 8, 380-392.	6.1	14
268	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1960-1970.	2.9	14
269	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	1.0	14
270	Ventilatory efficiency is unchanged after physical training in healthy persons despite an increase in exercise tolerance. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1994, 1, 347-351.	1.5	13

#	ARTICLE	IF	CITATIONS
271	Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 222-228.	1.5	13
272	Superiority of endothelin-1 over norepinephrine in exercise-induced alterations of the conduit artery tone of the non-exercised arm in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2000, 73, 15-25.	0.8	13
273	CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI. <i>International Journal of Cardiology</i> , 2001, 78, 109-113.	0.8	13
274	Influence of valve prosthesis type on the recovery of ventricular dysfunction and subendocardial ischaemia following valve replacement for aortic stenosis. <i>International Journal of Cardiology</i> , 2004, 97, 535-541.	0.8	13
275	Carvedilol reduces the costs of medical care in severe heart failure: An economic analysis of the COPERNICUS study applied to the United Kingdom. <i>International Journal of Cardiology</i> , 2005, 100, 143-149.	0.8	13
276	The Research Quality Framework and its implications for health and medical research: time to take stock?. <i>Medical Journal of Australia</i> , 2006, 184, 463-466.	0.8	13
277	The Effect of Estrogen on Blood Pressure in Hypertensive Postmenopausal Women. <i>Menopause</i> , 1997, 4, 115-119.	0.8	12
278	Defects in insulin action in chronic heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 203-212.	2.2	12
279	Clinical trials, treatment guidelines and real life. <i>International Journal of Cardiology</i> , 2000, 73, 205-207.	0.8	12
280	Assessment of chemoreflex sensitivity in free breathing young subjects by correction for respiratory influence. <i>International Journal of Cardiology</i> , 2001, 78, 157-165.	0.8	12
281	Incremental Importance of Peak-Exercise Plasma Levels of Endothelin-1 and Natriuretic Peptides in Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, 468-473.	0.8	12
282	Reproducibility of the measurement of the muscle ergoreflex activity in chronic heart failure. <i>European Journal of Heart Failure</i> , 2003, 5, 453-461.	2.9	12
283	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2185-2195.	1.0	12
284	Origins of symptoms in heart failure. , 1997, 11, 265-272.		11
285	Exercise endpoints in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2000, 73, 61-66.	0.8	11
286	Redefining heart failure. <i>International Journal of Cardiology</i> , 2006, 112, 139-141.	0.8	11
287	British Hypertension Protocol. <i>Journal of Hypertension</i> , 1991, 9, 575-576.	0.3	10
288	Age and Blood Pressure Measurement: Experience with the TM2420 Ambulatory Blood Pressure Monitor and Elderly People. <i>Age and Ageing</i> , 1992, 21, 398-403.	0.7	10

#	ARTICLE	IF	CITATIONS
289	Factors which alter the relationship between ventilation and carbon dioxide production during exercise in normal subjects. <i>European Journal of Applied Physiology and Occupational Physiology</i> , 1996, 73, 144-148.	1.2	10
290	Oscillations in Stroke Volume and Cardiac Output Arising from Oscillatory Ventilation in Humans. <i>Experimental Physiology</i> , 2000, 85, 857-862.	0.9	10
291	The importance and complexity of neurohumeral over-activity in chronic heart failure. <i>International Journal of Cardiology</i> , 2000, 73, 13-14.	0.8	10
292	Validation of a treadmill exercise test protocol with improved metabolic plateau formation in patients with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2001, 87, 1328-1331.	0.7	10
293	Association of Deranged Adrenal Steroid Metabolism With Anemia in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2005, 96, 101-103.	0.7	10
294	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	1.4	10
295	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
296	Definition and Classification of Heart Failure. <i>International Cardiovascular Forum Journal</i> , 0, 10, .	1.1	10
297	Validation of Ambulatory Monitors in Special Populations. <i>American Journal of Hypertension</i> , 1992, 5, 664-669.	1.0	9
298	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125.	1.8	9
299	Effects of nebivolol on biomarkers in elderly patients with heart failure. <i>International Journal of Cardiology</i> , 2014, 175, 253-260.	0.8	9
300	The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure. <i>International Journal of Cardiology</i> , 2016, 212, 187-189.	0.8	9
301	Impact of periodic breathing on and : a quantitative approach by Fourier analysis. <i>Respiration Physiology</i> , 1999, 118, 247-255.	2.8	8
302	Angiotensin type-1 receptor blockers in heart failure. <i>Progress in Cardiovascular Diseases</i> , 2002, 44, 231-242.	1.6	8
303	Impact of sleep disordered breathing severity on hemodynamics, autonomic balance and cardiopulmonary functional status in chronic heart failure. <i>International Journal of Cardiology</i> , 2010, 141, 227-235.	0.8	8
304	Functional outcomes with Carillon device over 1Âyear in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCEâ€FMR trial. <i>ESC Heart Failure</i> , 2021, 8, 872-878.	1.4	8
305	Sympathetic Stimulations by Exercise-Stress Testing and by Dobutamine Infusion Induce Similar Changes in Heart Rate Variability in Patients with Chronic Heart Failure. <i>Clinical Science</i> , 1995, 89, 155-164.	1.8	7
306	Role of Catecholamines and Sympathetic Activation as a Risk Factor for Coronary Artery Disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 222-228.	3.1	7

#	ARTICLE	IF	CITATIONS
307	Myocardial revascularisation: the search for the Holy Grail. <i>International Journal of Cardiology</i> , 2000, 73, 1-2.	0.8	7
308	Omapatrilat â€” the ups and downs of an exciting but complicated new drug. <i>International Journal of Cardiology</i> , 2000, 74, 1-3.	0.8	7
309	Chronic stable angina and its treatment; Why Cinderella never gets to the ball?. <i>International Journal of Cardiology</i> , 2000, 76, 97-99.	0.8	7
310	Welcome to Tsung O Cheng, Roving Ambassador for Chinese Cardiovascular Science. <i>International Journal of Cardiology</i> , 2007, 117, 1-2.	0.8	7
311	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist deviceâ€”supported patients for the nonâ€”left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
312	Chemoreceptor-Baroreceptor Interactions in Cardiovascular Disease. <i>Lung Biology in Health and Disease</i> , 2000, , 33-60.	0.1	7
313	Doppler ultrasound signal analysis based on the TMS320 signal processor. <i>Journal of Biomedical Engineering</i> , 1988, 10, 127-129.	0.7	6
314	Autonomic Abnormality in Chronic Heart Failure Evaluated by Heart Rate Variability. <i>Clinical Science</i> , 1996, 91, 84-86.	0.0	6
315	Making choices in cardiology: difficulties of rationing and equality of access. <i>International Journal of Cardiology</i> , 2001, 78, 209-212.	0.8	6
316	Adult Congenital Heart Disease in the <i>International Journal of Cardiology</i> . <i>International Journal of Cardiology</i> , 2003, 88, 125-126.	0.8	6
317	Eplerenone's role in the management of complex cardiovascular disorders. <i>International Journal of Cardiology</i> , 2015, 200, 1-2.	0.8	6
318	A comparison of research into cachexia, wasting and related skeletal muscle syndromes in three chronic disease areas. <i>International Journal of Cardiology</i> , 2017, 235, 33-36.	0.8	6
319	Exercise for Frail, Elderly Patients with Acute Heart Failure â€” A Strong Step Forward. <i>New England Journal of Medicine</i> , 2021, 385, 276-277.	13.9	6
320	Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. <i>Drugs</i> , 2021, 81, 1599-1604.	4.9	6
321	Exercise hyperventilation chronic congestive heart failure and its relation to functional capacity and hemodynamics. <i>American Journal of Cardiology</i> , 1993, 71, 1007-1008.	0.7	5
322	Relationship between arterial potassium and ventilation during exercise in patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , 1995, 1, 133-141.	0.7	5
323	Interruption of the Progression of Heart Failure: Are ACE Inhibitors the Solution?. <i>Cardiology</i> , 1996, 87, 11-15.	0.6	5
324	Teaching heart-failure patients how to breathe. <i>Lancet, The</i> , 1998, 351, 1299-1300.	6.3	5

#	ARTICLE	IF	CITATIONS
325	Inflammation, hormones, the blood and the heart; are cardiologists learning to be internists again? International Journal of Cardiology, 2000, 72, 203-205.	0.8	5
326	The effect of the localization of Q wave myocardial infarction on ventricular electromechanics. International Journal of Cardiology, 2002, 84, 241-247.	0.8	5
327	Abnormal temporal dynamics of blood pressure and RR interval regulation in patients with chronic heart failure: relationship to baroreflex sensitivity. International Journal of Cardiology, 2002, 86, 107-114.	0.8	5
328	The top papers by download and citations from the International Journal of Cardiology in 2007. International Journal of Cardiology, 2008, 131, e1-e3.	0.8	5
329	Support for exercise training in CHF. Nature Reviews Cardiology, 2009, 6, 447-448.	6.1	5
330	Reduced Confounding by Impaired Ventilatory Function With Oxygen Uptake Efficiency Slope and VE/VCO ₂ Slope Rather Than Peak Oxygen Consumption to Assess Exercise Physiology in Suspected Heart Failure. Congestive Heart Failure, 2010, 16, 259-264.	2.0	5
331	Impact Factor: Vagaries, inconsistencies and illogicalities; should it be abandoned?. International Journal of Cardiology, 2015, 201, 454-456.	0.8	5
332	Heart failure management of the elderly patient: focus on frailty, sarcopaenia, cachexia, and dementia: conclusions. European Heart Journal Supplements, 2019, 21, L36-L38.	0.0	5
333	Vericiguat for heart failure and the VICTORIA trial – the dog that didn't bark?. European Journal of Heart Failure, 2020, 22, 576-577.	2.9	5
334	The Altmetric Attention Score: how science tries to meet social media. European Journal of Heart Failure, 2021, 23, 693-697.	2.9	5
335	The ever-changing field of mechanical circulatory support: new challenges at the advent of the “single device era”. European Journal of Heart Failure, 2021, 23, 1428-1431.	2.9	5
336	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	1.4	5
337	ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management. European Heart Journal, 2021, 43, 11-13.	1.0	5
338	“Peptide for Life”™ in primary care: work in progress. European Heart Journal, 2021, , .	1.0	5
339	Skeletal muscle metabolism in experimental heart failure: Effects of infarct size and physical training. Journal of the American College of Cardiology, 1991, 17, A158.	1.2	4
340	New evidence for improved survival in chronic heart failure. Clinical Cardiology, 1994, 17, 55-58.	0.7	4
341	Five years of progress for International Journal of Cardiology. International Journal of Cardiology, 2005, 100, 173-175.	0.8	4
342	Validating the HFA-PEFF score – or how to define a disease?. European Journal of Heart Failure, 2020, 22, 428-431.	2.9	4

#	ARTICLE	IF	CITATIONS
343	Therapeutic Interventions to Reduce Rates of Hospitalization and Death in Patients with Heart Failure: New Clinical Evidence. <i>Cardiology</i> , 1992, 81, 1-7.	0.6	3
344	What do Cochrane reviews tell us about anti-thrombotic therapy in heart failure with sinus rhythm?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002, 95, 419-421.	0.2	3
345	Human pituitary growth hormone and cancer risk. <i>Lancet, The</i> , 2002, 360, 1791-1792.	6.3	3
346	Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern. <i>American Journal of Cardiology</i> , 2003, 91, 1281-1283.	0.7	3
347	Anemia and inflammation in chronic heart failure. <i>Journal of Cardiac Failure</i> , 2003, 9, S33.	0.7	3
348	Nutritional Status in Advanced Heart Failure and Heart Transplant Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 626-628.	0.4	3
349	Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail. <i>European Heart Journal</i> , 2021, 42, 1637-1637.	1.0	3
350	Baroreflex control of stroke volume: A vagal mediated effect. <i>Journal of the American College of Cardiology</i> , 1991, 17, A146.	1.2	2
351	Ventilatory Efficiency is Unchanged after Physical Training in Healthy Persons Despite an increase in Exercise Tolerance. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1994, 1, 347-351.	3.1	2
352	Non-elective intra-coronary stenting: are the clinical outcomes comparable to elective stenting at 6 months?. <i>International Journal of Cardiology</i> , 1999, 71, 121-127.	0.8	2
353	Increased Urinary Cortisol and Androgen Metabolites in a Young Female with Hypertension: Partial Glucocorticoid Resistance Syndrome. <i>Cardiology</i> , 2000, 93, 131-132.	0.6	2
354	Round table on "Current evidence and future perspectives on ω 3 PUFA". <i>International Journal of Cardiology</i> , 2013, 170, S1-S2.	0.8	2
355	Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial. <i>International Journal of Cardiology</i> , 2014, 176, 600-604.	0.8	2
356	Consensus Meeting on "Uric Acid and Cardiovascular Risk" held at University Magna Graecia, Catanzaro, Italy, May 2014. Publication of the Proceedings as a special issue in the <i>International Journal of Cardiology</i> . <i>International Journal of Cardiology</i> , 2016, 213, 1-3.	0.8	2
357	News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 261-263.	2.9	2
358	Monitoring for sleep-disordered breathing in heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M36-M39.	0.0	2
359	A Doppler derived index of diastolic function; Independent of preload, heart rate and atrio-ventricular interval. <i>Journal of the American College of Cardiology</i> , 1990, 15, A163.	1.2	1
360	Circadian blood pressure variation in diabetic patients with autonomic neuropathy. <i>Journal of Hypertension</i> , 1993, 11, 1139.	0.3	1

#	ARTICLE	IF	CITATIONS
361	Validation of blood pressure measuring devices. <i>Journal of Clinical Monitoring and Computing</i> , 1995, 11, 257-257.	0.6	1
362	Assessment of Chronic Heart Failure Using Gas Exchange: Which Variable and When to Correct for Body Mass. <i>Cardiology</i> , 1999, 91, 140-144.	0.6	1
363	The pathophysiology of chronic heart failure. <i>Perfusion (United Kingdom)</i> , 2000, 15, 281-286.	0.5	1
364	Anti-arrhythmic properties of moxonidine and the MOXCON story. <i>International Journal of Cardiology</i> , 2000, 74, 91-92.	0.8	1
365	Hemoglobin level is associated with adverse outcomes in patients with severe chronic heart failure: results from the COPERNICUS study. <i>Journal of Cardiac Failure</i> , 2003, 9, S58.	0.7	1
366	Use of carvedilol in the treatment of heart failure. <i>British Journal of Hospital Medicine</i> , 2003, 64, 288-291.	0.3	1
367	Top downloads from the <i>International Journal of Cardiology</i> entering 2006. <i>International Journal of Cardiology</i> , 2006, 106, 1-2.	0.8	1
368	Most frequently cited and downloaded papers from Volume 98 (2005). <i>International Journal of Cardiology</i> , 2007, 122, e16-e17.	0.8	1
369	Chronic Heart Failure, Nutritional Status and Survival. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 743-744.	0.4	1
370	Reply to the Hong-Lin Chen article on CONSORT (2010) recommendations. <i>International Journal of Cardiology</i> , 2012, 162, 4-5.	0.8	1
371	Beware of putting too much trust in PubMed: A lesson from Hong-Lin Chen's article on adherence to CONSORT (2010) recommendations. <i>International Journal of Cardiology</i> , 2013, 168, 1643.	0.8	1
372	The importance of China (and Tsung O Cheng, International Consulting Editor for China) to the <i>International Journal of Cardiology</i> . <i>International Journal of Cardiology</i> , 2015, 199, 303-306.	0.8	1
373	Central sleep apnoea in heart failure – An important issue for the modern heart failure cardiologist. <i>International Journal of Cardiology</i> , 2016, 206, S1-S3.	0.8	1
374	Measuring therapeutic efficacy in the treatment of central sleep apnoea in patients with heart failure. <i>International Journal of Cardiology</i> , 2016, 206, S16-S21.	0.8	1
375	Early abnormalities of cerebral blood flow in mild non-ischaemic heart failure: part of a whole-body response?. <i>European Journal of Heart Failure</i> , 2017, 19, 269-270.	2.9	1
376	Cachexia therapies – the need to take a broader look. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1581-1582.	1.4	1
377	Intravenous ferric carboxymaltose for heart failure with iron deficiency. <i>European Journal of Heart Failure</i> , 2018, 20, 134-135.	2.9	1
378	Targeting breathlessness in heart failure. <i>ESC Heart Failure</i> , 2019, 6, 1103-1104.	1.4	1

#	ARTICLE	IF	CITATIONS
379	Heart Failure Association position papers – a new way to advance the field. <i>European Journal of Heart Failure</i> , 2020, 22, 6-7.	2.9	1
380	Figures of the Heart Failure Association (HFA): Prof. Dr. Tiny Jaarsma, HFA Board Member (2018–2020), Coordinator Patient Care: Management and Delivery Committee and Co-Chair HFA Task Force on Palliative Care. <i>European Journal of Heart Failure</i> , 2020, 22, 3-5.	2.9	1
381	Oscillations in Stroke Volume and Cardiac Output Arising from Oscillatory Ventilation in Humans. , 2000, 85, 857.		1
382	Handling Complexity in Oxygen Delivery in the Univentricular Circulation. <i>Circulation</i> , 1999, 100, 211-214.	1.6	1
383	Detection of Early Heart Failure with Preserved Ejection Fraction (HFpEF) in Metabolic Syndrome Patients Detected as Part of a National Screening Programme in Middle Aged Subjects. <i>International Cardiovascular Forum Journal</i> , 0, 13, .	1.1	1
384	Takotsubo Syndrome: A Complex and Varied Clinical Syndrome. <i>International Cardiovascular Forum Journal</i> , 0, 5, .	1.1	1
385	Feasibility of the cardiac output response to stress test in suspected heart failure patients. <i>Family Practice</i> , 2022, , .	0.8	1
386	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	1
387	Controlled trial of physical training in moderate to severe heart failure. <i>Journal of the American College of Cardiology</i> , 1990, 15, A258.	1.2	0
388	Are we underestimating the risk of hypertension by the use of too few BP estimations?. <i>Journal of the American College of Cardiology</i> , 1990, 15, A141.	1.2	0
389	Placebo-controlled, cross-over trial of physical training, lisinopril and the combination in moderate to severe heart failure. <i>Journal of the American College of Cardiology</i> , 1991, 17, A275.	1.2	0
390	The heart rate-independent effects of inotropic stimulation and afterload augmentation on atrial performance. <i>Journal of the American College of Cardiology</i> , 1991, 17, A332.	1.2	0
391	Heart function in health and disease. <i>International Journal of Cardiology</i> , 1993, 41, 184-185.	0.8	0
392	Bone loss in cardiac cachectic CHF patients. <i>Journal of the American College of Cardiology</i> , 1996, 27, 337-338.	1.2	0
393	Pulmonary Clearance of Endothelin-1 on Heart Failure: Reduced or Normal?. <i>Circulation</i> , 1999, 100, e135.	1.6	0
394	Exercise Training in Heart Failure: When?. <i>Heart Failure Reviews</i> , 1999, 3, 299-303.	1.7	0
395	Hemoglobin independently predicts exercise capacity in anemic patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , 2003, 9, S14.	0.7	0
396	Dyspnoea in CHF and COPD. <i>International Journal of Cardiology</i> , 2005, 105, 351.	0.8	0

#	ARTICLE	IF	CITATIONS
397	Erratum to "Five years of progress for international journal of cardiology" [International Journal of Cardiology 97 (2004) 343-344]. International Journal of Cardiology, 2005, 100, 171.	0.8	0
398	25 years at the International Journal of Cardiology "What has changed and what hasn't. International Journal of Cardiology, 2007, 115, e61-e62.	0.8	0
399	PCV27 ECONOMIC EVALUATION OF NEBIVOLOL COMPARED WITH PLACEBO IN ELDERLY PATIENTS WITH HEART FAILURE -A MODEL BASED ANALYSIS ALONGSIDE THE SENIORS TRIAL. Value in Health, 2007, 10, A413.	0.1	0
400	Scientific deception: retraction of a fraudulent paper. Phytotherapy Research, 2008, 22, 1698-1698.	2.8	0
401	Most frequently cited and downloaded papers from volumes 99 and 100. International Journal of Cardiology, 2008, 123, e23-e24.	0.8	0
402	Inconsistencies in the development of the ESC Clinical Practice Guidelines for Heart Failure. International Journal of Cardiology, 2013, 168, 1724-1727.	0.8	0
403	Sacubitril/valsartan: Can haemodynamic monitoring help with up-take?. International Journal of Cardiology, 2018, 271, 202-203.	0.8	0
404	Figures of the Heart Failure Association: Dr. Ovidiu Chioncel, HFA Board Member, 2018-2020. European Journal of Heart Failure, 2019, 21, 953-954.	2.9	0
405	Activities of the study groups "The Study Group on Takotsubo Syndrome. European Journal of Heart Failure, 2019, 21, 1054-1056.	2.9	0
406	When is an implantable cardioverter-defibrillator controversial?. European Journal of Heart Failure, 2019, 21, 1504-1506.	2.9	0
407	Technology-assisted clinical care. European Journal of Heart Failure, 2019, 21, 1088-1089.	2.9	0
408	Drug dosing for heart failure: does sex or size matter?. Nature Reviews Cardiology, 2019, 16, 705-706.	6.1	0
409	Figures of the Heart Failure Association (HFA): Prof. Dr. Jelena "Elutkien", HFA Board Member (2016-2020) and coordinator of the Imaging Study Group of the HFA Diagnosis Committee. European Journal of Heart Failure, 2019, 21, 1487-1489.	2.9	0
410	Figures of the Heart Failure Association: Prof. Dr. Lars Lund, Chair of the HFA Committee on Registries, Surveys and Epidemiology and HFA Board Member (from 2016). European Journal of Heart Failure, 2020, 22, 1941-1944.	2.9	0
411	National Heart Failure Societies Summit 2020. European Journal of Heart Failure, 2021, 23, 507-510.	2.9	0
412	Treatments delayed lead to lives lost. European Journal of Heart Failure, 2021, 23, 511-511.	2.9	0
413	The Heart Failure Association further develops its educational engagement working together on a Masters of Science in heart failure with St George's Hospital in London. European Journal of Heart Failure, 2021, 23, 1422-1423.	2.9	0
414	Figures of the Heart Failure Association: Loreena Hill (HFA Board Member and Nurse) European Journal of Heart Failure, 2021, 23, 1572-1573.	2.9	0

#	ARTICLE	IF	CITATIONS
415	Figures of the Heart Failure Association: Professor Dr. Wilfried Mullens, Board Member, 2018â€“2022, Coordinator of the Study Group on Cardiorenal Dysfunction and the Committee on Cardiac Devices, Deputy on Certification of the Committee on Education. European Journal of Heart Failure, 2021, 23, 1574-1576.	2.9	0
416	Nonpharmacological Therapies. , 2010, , 277-288.		0
417	Training for the Enhancement of Exercise Tolerance in Patients with Left Ventricular Dysfunction. , 1996, , 287-295.		0
418	A Welcome to the New Journal, Journal of Advanced Therapies and Medical Innovation Science (j.ATAMIS).. Journal of Advanced Therapies and Medical Innovation Sciences, 0, 1, .	0.0	0
419	The Potential of Devices for HFpEF. International Cardiovascular Forum Journal, 0, 10, .	1.1	0
420	The Management of Co-Morbidities in Patients with Heart Failure â€“ Lung Disorders. International Cardiovascular Forum Journal, 0, 10, .	1.1	0
421	The Management of Co-Morbidities in Patients with Heart Failure â€“ Obstructive Sleep Apnoea. International Cardiovascular Forum Journal, 0, 10, .	1.1	0
422	The Management of Co-Morbidities in Patients with Heart Failure â€“ Central Sleep Apnoea. International Cardiovascular Forum Journal, 0, 10, .	1.1	0
423	Other Devices for Heart Failure â€“ Cardiac Contractility Modulation (CCM). International Cardiovascular Forum Journal, 0, 10, .	1.1	0
424	Association Between ApoE Polymorphism in Obesity Markers in Healthy Adults Who Follow the Greek Orthodox Fasting Rules. International Cardiovascular Forum Journal, 0, 15, .	1.1	0
425	Victoria Trial: Vericiguat Joins the Big League, or Does it?. International Cardiovascular Forum Journal, 0, 19, .	1.1	0
426	Pulmonary artery pressure monitoring, a reality for Europe?. European Journal of Heart Failure, 2020, 22, 1905-1906.	2.9	0
427	Figures of the Heart Failure Association: Professor Finn Gustafsson, Board Member, 2020â€“2022. European Journal of Heart Failure, 2022, 24, 738-740.	2.9	0
428	What's all the fuss about a new guideline?. European Journal of Heart Failure, 2022, 24, 743-745.	2.9	0